The HDI romidepsin was able to improve erlotinib anti-tumour effect in nine NSCLC lines with varying histology and mutation conditions, including EGFR-, KRAS-mutant, and wild type cell lines, with a decrease in tumour load in NCI-H1299 xenograft models [105]. Here, EGFR is linked to non-small cell lung carcinoma.